Amcasertib -Boston Biomedical

Drug Profile

Amcasertib -Boston Biomedical

Alternative Names: BB503; BBI 503; GB-503

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boston Biomedical
  • Developer Boston Biomedical; Sumitomo Dainippon Pharma
  • Class Antineoplastics; Indoles; Pyrroles; Small molecules; Thiazoles
  • Mechanism of Action Cell death stimulants; Phosphotransferase inhibitors; Protein-serine-threonine kinase inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Gastrointestinal stromal tumours; Hepatocellular carcinoma; Ovarian cancer; Solid tumours

Most Recent Events

  • 07 Jul 2017 Boston Biomedical withdraws a phase II trial prior to enrolment due to low feasibility for Urogenital cancer (Late-stage disease, Metastatic disease, Unresectable/ Inoperable, Recurrent, Second-line therapy or greater) in USA and Canada (PO) (NCT02232646)
  • 14 Jun 2017 Efficacy and adverse events data from a phase Ib/II trial in solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO 2017)
  • 05 Jun 2017 Interim efficacy and adverse events data from a phase Ib/II trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top